Contribution of prognostic factors to adjuvant chemotherapy in breast cancer.
作者信息
Bonadonna G, Valagussa P
出版信息
Recent Results Cancer Res. 1984;96:34-45. doi: 10.1007/978-3-642-82357-2_5.
PMID:6528090
Abstract
摘要
相似文献
1
Contribution of prognostic factors to adjuvant chemotherapy in breast cancer.
Recent Results Cancer Res. 1984;96:34-45. doi: 10.1007/978-3-642-82357-2_5.
2
The clinical scientific basis of adjuvant chemotherapy in breast cancer.乳腺癌辅助化疗的临床科学依据。
Recent Results Cancer Res. 1984;96:8-17. doi: 10.1007/978-3-642-82357-2_2.
3
Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.21 基因复发评分检测对淋巴结阴性、雌激素受体阳性乳腺癌辅助治疗选择中标准临床病理指南的影响。
Ann Surg Oncol. 2011 Nov;18(12):3399-406. doi: 10.1245/s10434-011-1698-z. Epub 2011 May 3.
4
Ludwig Breast Cancer trial LBCS III: chemo- and endocrine adjuvant treatment in postmenopausal patients.路德维希乳腺癌试验LBCS III：绝经后患者的化疗和内分泌辅助治疗。
Recent Results Cancer Res. 1984;96:102-9. doi: 10.1007/978-3-642-82357-2_12.
5
Are current worldwide studies going to answer the important questions remaining in adjuvant chemotherapy of breast cancer?
Recent Results Cancer Res. 1984;96:224-36. doi: 10.1007/978-3-642-82357-2_29.
6
[Significance of hormone receptors of breast cancer cells for the duration of a disease-free interval].[乳腺癌细胞激素受体对无病生存期的意义]
Wien Klin Wochenschr. 1985 May 24;97(11):493-7.
7
Significant survival benefit of node-negative breast cancer patients treated with adjuvant chemotherapy: seven-year results.辅助化疗治疗的淋巴结阴性乳腺癌患者具有显著生存获益：七年结果
Recent Results Cancer Res. 1989;115:180-5. doi: 10.1007/978-3-642-83337-3_26.
8
Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients.高危乳腺癌的辅助全身治疗：丹麦乳腺癌协作组关于绝经前患者使用环磷酰胺或CMF以及绝经后患者使用他莫昔芬的试验。
Recent Results Cancer Res. 1984;96:117-28. doi: 10.1007/978-3-642-82357-2_14.
9
[Current status of treatment for early-stage invasive breast cancer].[早期浸润性乳腺癌的治疗现状]
Orv Hetil. 2009 May 31;150(22):1013-21. doi: 10.1556/OH.2009.28615.
10
The NIH Consensus Development Conference on Adjuvant Chemotherapy for Breast Cancer--a commentary.
Breast Cancer Res Treat. 1985;6(3):195-200. doi: 10.1007/BF01806769.
引用本文的文献
1
Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer.标记指数与雌激素受体及肿瘤大小在淋巴结阴性乳腺癌中的预后意义
Breast Cancer Res Treat. 1986;7(3):161-9. doi: 10.1007/BF01806246.
Zotero 插件